{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:18:59Z","timestamp":1785449939371,"version":"3.56.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Lundbeck LLC"},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Despite recent advancements in migraine treatment, some patients continue to endure significant disease burden. Due to the controlled nature of randomized trials in migraine prevention, many real-world patients with comorbidities or prior exposure to certain therapies are excluded. Capturing evidence of the effectiveness of treatment in real-world clinical settings can further shape treatment paradigms. The objective of this study was to develop a comprehensive understanding of both patients\u2019 and physicians\u2019 real-world experiences with eptinezumab for chronic migraine (CM).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>REVIEW (Real-world EVidence and Insights into Experiences With eptinezumab) is an observational, multi-site (<jats:italic>n<\/jats:italic>\u2009=\u20094), US-based study designed to evaluate real-world experiences of patients treated with eptinezumab and their treating physicians. Patients were \u2265\u200918 years of age, with a diagnosis of CM, who had completed\u2009\u2265\u20092 consecutive eptinezumab infusion cycles (\u2265\u20096 months of exposure). The study included a retrospective chart review, a patient survey, and a semi-structured physician interview that assessed patient and\/or physician satisfaction with elements of daily living \/ well-being, migraine symptomology, and perspectives of the eptinezumab infusion experience.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 94 patients enrolled, 83% (78\/94) were female, the mean age was 49.2 years, and the mean time since migraine diagnosis was 15.4 years. Before eptinezumab treatment, patients experienced a mean of 8 self-reported \u201cgood\u201d days\/month, which increased to 18 after treatment. Most patients took, on average, \u2265\u200910 days\/month of prescription and\/or over-the-counter medication (81% [75\/93] and 66% [61\/93], respectively) to treat migraine attacks before eptinezumab treatment, which dropped to 26% (24\/93) and 23% (21\/93) following eptinezumab treatment. Prior to receiving eptinezumab, 62% (58\/93) of patients indicated being at least slightly concerned about infusions; after eptinezumab infusion, this dropped to 14% (13\/93). These patient survey findings were consistent with physician responses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This real-world evidence study demonstrated high overall satisfaction with the effectiveness of eptinezumab treatment for CM among most patients and their physicians.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-024-01764-9","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T07:01:56Z","timestamp":1714028516000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based study"],"prefix":"10.1186","volume":"25","author":[{"given":"Charles","family":"Argoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer V.","family":"Kotak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Sopina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonna","family":"Saltarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Soni-Brahmbhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawad A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"issue":"1","key":"1764_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/head.14024","volume":"61","author":"R Burch","year":"2021","unstructured":"Burch R, Rizzoli P, Loder E (2021) The prevalence and impact of migraine and severe headache in the United States: updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache 61(1):60\u201368. https:\/\/doi.org\/10.1111\/head.14024","journal-title":"Headache"},{"issue":"4","key":"1764_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.ncl.2019.07.009","volume":"37","author":"K Greene","year":"2019","unstructured":"Greene K, Irwin SL, Gelfand AA (2019) Pediatric migraine: an update. Neurol Clin 37(4):815\u2013833. https:\/\/doi.org\/10.1016\/j.ncl.2019.07.009","journal-title":"Neurol Clin"},{"issue":"7","key":"1764_CR3","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/head.14154","volume":"61","author":"R Ishii","year":"2021","unstructured":"Ishii R, Schwedt TJ, Dumkrieger G, Lalvani N, Craven A, Goadsby PJ et al (2021) Chronic versus episodic migraine: the 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. Headache 61(7):992\u20131003. https:\/\/doi.org\/10.1111\/head.14154","journal-title":"Headache"},{"issue":"10","key":"1764_CR4","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1111\/head.13966","volume":"60","author":"DC Buse","year":"2020","unstructured":"Buse DC, Reed ML, Fanning KM, Bostic RC, Lipton RB (2020) Demographics, headache features, and comorbidity profiles in relation to headache frequency in people with migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache 60(10):2340\u20132356. https:\/\/doi.org\/10.1111\/head.13966","journal-title":"Headache"},{"issue":"8","key":"1764_CR5","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/head.13613","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse DC, Fanning KM, Reed ML, Murray S, Dumas PK, Adams AM et al (2019) Life with migraine: effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache 59(8):1286\u20131299. https:\/\/doi.org\/10.1111\/head.13613","journal-title":"Headache"},{"issue":"3","key":"1764_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0333102410381145","volume":"31","author":"AM Blumenfeld","year":"2011","unstructured":"Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A et al (2011) Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the international burden of migraine study (IBMS). Cephalalgia 31(3):301\u2013315. https:\/\/doi.org\/10.1177\/0333102410381145","journal-title":"Cephalalgia"},{"issue":"7","key":"1764_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/0333102414552532","volume":"35","author":"AM Adams","year":"2015","unstructured":"Adams AM, Serrano D, Buse DC, Reed ML, Marske V, Fanning KM et al (2015) The impact of chronic migraine: the chronic migraine epidemiology and outcomes (CaMEO) study methods and baseline results. Cephalalgia 35(7):563\u2013578. https:\/\/doi.org\/10.1177\/0333102414552532","journal-title":"Cephalalgia"},{"issue":"5","key":"1764_CR8","doi-asserted-by":"publisher","first-page":"e16187","DOI":"10.1016\/j.heliyon.2023.e16187","volume":"9","author":"P Yalinay Dikmen","year":"2023","unstructured":"Yalinay Dikmen P, Ozge A, Martelletti P (2023) The use of clinical scales and PROMs in headache disorders and migraine, summarizing their dissemination and operationalization. Heliyon 9(5):e16187. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16187","journal-title":"Heliyon"},{"issue":"1","key":"1764_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s10194-019-1040-x","volume":"20","author":"L D\u2019Antona","year":"2019","unstructured":"D\u2019Antona L, Matharu M (2019) Identifying and managing refractory migraine: barriers and opportunities? J Headache Pain 20(1):89. https:\/\/doi.org\/10.1186\/s10194-019-1040-x","journal-title":"J Headache Pain"},{"key":"1764_CR10","unstructured":"Botox [package insert] (2023) Madison, NJ: Allergan"},{"issue":"5","key":"1764_CR11","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/head.13529","volume":"59","author":"S Iyengar","year":"2019","unstructured":"Iyengar S, Johnson KW, Ossipov MH, Aurora SK (2019) CGRP and the trigeminal system in migraine. Headache 59(5):659\u2013681. https:\/\/doi.org\/10.1111\/head.13529","journal-title":"Headache"},{"key":"1764_CR12","unstructured":"VYEPTI [package insert], Bothell (2022) WA: Lundbeck Seattle BioPharmaceuticals, Inc."},{"key":"1764_CR13","volume-title":"North Wales","author":"AJOVY [package insert]","year":"2022","unstructured":"AJOVY [package insert] (2022) North Wales. Teva Pharmaceuticals USA, Inc., PA"},{"key":"1764_CR14","unstructured":"EMGALITY [package insert], Indianapolis (2021) IN: Eli Lilly and Company"},{"key":"1764_CR15","unstructured":"AIMOVIG [package insert] (2023) Thousand Oaks, CA: Amgen Inc."},{"key":"1764_CR16","doi-asserted-by":"publisher","unstructured":"Baker B, Schaeffler B, Cady R, Latham J, Whitaker T, Smith J (2017) Rational design of a monoclonal antibody (mAB) inhibiting calcitonin gene-related peptide (CGRP), ALD403, intended for the prevention of migraine (p2.155). Neurology 88(16 Supplement). https:\/\/doi.org\/10.1212\/WNL.88.16_supplement.P2.155","DOI":"10.1212\/WNL.88.16_supplement.P2.155"},{"issue":"7","key":"1764_CR17","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","volume":"21","author":"M Ashina","year":"2022","unstructured":"Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK et al (2022) Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 21(7):597\u2013607. https:\/\/doi.org\/10.1016\/S1474-4422(22)00185-5","journal-title":"Lancet Neurol"},{"issue":"3","key":"1764_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J et al (2020) Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40(3):241\u2013254. https:\/\/doi.org\/10.1177\/0333102420905132","journal-title":"Cephalalgia"},{"issue":"13","key":"1764_CR19","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94(13):e1365\u2013e77. https:\/\/doi.org\/10.1212\/WNL.0000000000009169","journal-title":"Neurology"},{"issue":"23","key":"1764_CR20","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1001\/jama.2021.7665","volume":"325","author":"PK Winner","year":"2021","unstructured":"Winner PK, McAllister P, Chakhava G, Ailani J, Ettrup A, Krog Josiassen M et al (2021) Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial. JAMA 325(23):2348\u20132356. https:\/\/doi.org\/10.1001\/jama.2021.7665","journal-title":"JAMA"},{"issue":"1","key":"1764_CR21","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12883-021-02123-w","volume":"21","author":"D Kudrow","year":"2021","unstructured":"Kudrow D, Cady RK, Allan B, Pederson SM, Hirman J, Mehta LR et al (2021) Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurol 21(1):126. https:\/\/doi.org\/10.1186\/s12883-021-02123-w","journal-title":"BMC Neurol"},{"issue":"5","key":"1764_CR22","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s40120-023-00521-5","volume":"12","author":"Y Bader","year":"2023","unstructured":"Bader Y, Suliman R, Harb M, Santos V, Al Qaisi I, Alsaadi T (2023) Effectiveness and safety of eptinezumab in episodic and chronic migraine headache in the UAE: a retrospective study. Neurol Ther 12(5):1683\u20131693. https:\/\/doi.org\/10.1007\/s40120-023-00521-5","journal-title":"Neurol Ther"},{"issue":"4\u20135","key":"1764_CR23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/03331024211048765","volume":"42","author":"LH Overeem","year":"2022","unstructured":"Overeem LH, Peikert A, Hofacker MD, Kamm K, Ruscheweyh R, Gendolla A et al (2022) Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia 42(4\u20135):291\u2013301. https:\/\/doi.org\/10.1177\/03331024211048765","journal-title":"Cephalalgia"},{"issue":"4","key":"1764_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.33588\/rn.7504.2021526","volume":"75","author":"Y Lopez-Moreno","year":"2022","unstructured":"Lopez-Moreno Y, Castro-Sanchez MV, Garcia-Trujillo L, Serrano-Castro P (2022) Failure of an anti-CGRP monoclonal antibody in the treatment of migraine. Is it worthwhile trying another one?. Rev Neurol 75(4):87\u201391. https:\/\/doi.org\/10.33588\/rn.7504.2021526","journal-title":"Rev Neurol"},{"issue":"8","key":"1764_CR25","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.nrleng.2020.10.008","volume":"36","author":"J Porta-Etessam","year":"2021","unstructured":"Porta-Etessam J, Gonzalez-Garcia N, Guerrero AL, Garcia-Azorin D (2021) Failure of monoclonal antibodies against CGRP or its receptor does not imply lack of efficacy of other drugs from the same class. Neurologia (Engl Ed) 36(8):638\u2013640. https:\/\/doi.org\/10.1016\/j.nrleng.2020.10.008","journal-title":"Neurologia (Engl Ed)"},{"key":"1764_CR26","unstructured":"Resources for Overcoming Migraine Treatment Insurance Barriers (2023) https:\/\/headachemigraine.org\/migraine-treatment-help\/. Accessed December 5"},{"issue":"1","key":"1764_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee o","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","journal-title":"Cephalalgia"},{"issue":"3","key":"1764_CR28","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1212\/cpj.0000000000001037","volume":"11","author":"TJ Schwedt","year":"2021","unstructured":"Schwedt TJ, Buse DC, Argoff CE, Reed ML, Fanning KM, Hussar CR et al (2021) Medication overuse and headache burden: results from the CaMEO study. Neurol Clin Pract 11(3):216\u2013226. https:\/\/doi.org\/10.1212\/cpj.0000000000001037","journal-title":"Neurol Clin Pract"},{"issue":"1","key":"1764_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s10194-018-0865-z","volume":"19","author":"TJ Schwedt","year":"2018","unstructured":"Schwedt TJ, Alam A, Reed ML, Fanning KM, Munjal S, Buse DC et al (2018) Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. J Headache Pain 19(1):38. https:\/\/doi.org\/10.1186\/s10194-018-0865-z","journal-title":"J Headache Pain"},{"issue":"8","key":"1764_CR30","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/j.1526-4610.2008.01217.x","volume":"48","author":"ME Bigal","year":"2008","unstructured":"Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB (2008) Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 48(8):1157\u20131168. https:\/\/doi.org\/10.1111\/j.1526-4610.2008.01217.x","journal-title":"Headache"},{"issue":"6","key":"1764_CR31","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/ane.13014","volume":"138","author":"D D\u2019Amico","year":"2018","unstructured":"D\u2019Amico D, Sansone E, Grazzi L, Giovannetti AM, Leonardi M, Schiavolin S et al (2018) Multimorbidity in patients with chronic migraine and medication overuse headache. Acta Neurol Scand 138(6):515\u2013522. https:\/\/doi.org\/10.1111\/ane.13014","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"1764_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s10194-022-01429-5","volume":"23","author":"SH Lo","year":"2022","unstructured":"Lo SH, Gallop K, Smith T, Powell L, Johnston K, Hubig LT et al (2022) Real-world experience of interictal burden and treatment in migraine: a qualitative interview study. J Headache Pain 23(1):65. https:\/\/doi.org\/10.1186\/s10194-022-01429-5","journal-title":"J Headache Pain"},{"key":"1764_CR33","doi-asserted-by":"publisher","unstructured":"Leiper DA, Elliott AM, Hannaford PC (2006) Experiences and perceptions of people with headache: a qualitative study. BMC Fam Pract 7(27). https:\/\/doi.org\/10.1186\/1471-2296-7-27","DOI":"10.1186\/1471-2296-7-27"},{"issue":"6","key":"1764_CR34","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V et al (2018) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38(6):1026\u20131037. https:\/\/doi.org\/10.1177\/0333102418759786","journal-title":"Cephalalgia"},{"issue":"9","key":"1764_CR35","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 75(9):1080\u20131088. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1212","journal-title":"JAMA Neurol"},{"issue":"8","key":"1764_CR36","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia 38(8):1442\u20131454. https:\/\/doi.org\/10.1177\/0333102418779543","journal-title":"Cephalalgia"},{"issue":"1","key":"1764_CR37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s10194-022-01486-w","volume":"23","author":"C Gonzalez-Mingot","year":"2022","unstructured":"Gonzalez-Mingot C, Gil-Sanchez A, Canudes-Solans M, Peralta-Moncusi S, Solana-Moga MJ, Brieva-Ruiz L (2022) Preventive treatment can reverse cognitive impairment in chronic migraine. J Headache Pain 23(1):121. https:\/\/doi.org\/10.1186\/s10194-022-01486-w","journal-title":"J Headache Pain"},{"issue":"4","key":"1764_CR38","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/head.14476","volume":"63","author":"TJ Schwedt","year":"2023","unstructured":"Schwedt TJ, Martin A, Kymes S, Talon B, Lee XY, Cady R et al (2023) Patient preferences for attributes of injected or infused preventive migraine medications: findings from a discrete choice experiment. Headache 63(4):484\u2013493. https:\/\/doi.org\/10.1111\/head.14476","journal-title":"Headache"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01764-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01764-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01764-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T07:02:04Z","timestamp":1714028524000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01764-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1764"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01764-9","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]},"assertion":[{"value":"13 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CA has served as a consultant for Lilly, Novartis, and Teva and has received honoraria from AbbVie, Amgen, Lilly, Novartis, Teva, and Theranica; he has received royalties from Elsevier for Pain Management Secrets and Raj\u2019s Practical Management of Pain. SPH reports receiving honoraria for speaker engagements from AbbVie. RMS reports no conflicts. SVK is an employee of Yorker Health, a company that received funding from Lundbeck LLC to conduct this study. LS is an independent contractor who received funding from Yorker Health for time spent to conduct this study. YS and SSB are employees of Lundbeck LLC. FAK reported receiving honoraria for speaker engagements from AbbVie, Allergan, Amgen, Impel Pharmaceuticals, Lilly, and Lundbeck; advisory fees from Pfizer; and institutional research support from AbbVie, Amgen, Biohaven Pharmaceutical, Lundbeck, and Teva.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"In collaboration with the academic authors, the sponsors participated in the design and conduct of the survey and in the collection, management, analysis, and interpretation of the data. The preparation, review, and approval of the manuscript was undertaken by all authors and by a professional medical writer and editor funded by the sponsors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the funder\/sponsor"}}],"article-number":"65"}}